| KIF20A peptide vaccine treatment | Best supportive care | |
---|---|---|---|
 | Chiba (n = 31) * | Chiba (n = 9) * | Multi-center (n = 81) ** |
Age (average, (range)) | 61.3 (33–80) | 64 (53–82) | 64.5 (41–85) |
Sex (Male: Female) | 17:14 | 5:4 | 49:32 |
Performance status (0:1:2:3) | 11:8:12:0 | 1:3:3:2 | 13:28:36:0 *** |
Status of primary lesion (Resected: Unresected) | 15:16 | 1:8 | 23:58 |
Median survival time (days) | 142.0 ± 23.7 | 83.0 ± 33.5 | 62.0 ± 6.5 |
Mean survival time (days) | 171.8 ± 23.8 | 93.3 ± 14.8 | 91.1 ± 11.6 |